Miller J J, Cole L J
J Exp Med. 1967 Jul 1;126(1):109-25. doi: 10.1084/jem.126.1.109.
The cells of the popliteal lymph nodes of rats were labeled for 4 days after a secondary immunological stimulus. 31 days after the last dose of tritiated thymidine, groups of rats were started on courses of daily, intraperitoneal injections of prednisone, cyclophosphamide, 6-mercaptopurine, or actinomycin D. The initially low doses of these agents were doubled in successive weeks until either lymphoid hypoplasia or death occurred. Rats from each group were killed weekly, and the percentages of persisting, labeled small lymphocytes in the popliteal nodes were determined. Sections of these nodes were examined for persisting, labeled plasma cells. The per cent of lymphocytes labeled increased while the total number of lymphocytes decreased during treatment with prednisone and cyclophosphamide. Prednisone decreased the numbers of long-lived plasma cells, but these cells were preferentially resistant to cyclophosphamide. Neither 6-mercaptopurine nor actinomycin D had an appreciable effect on lymphoid tissues histologically nor on the proportions of labeled, long-lived lymphocytes and plasma cells before causing the deaths of the rats receiving them. These results indicate that long-lived lymphocytes and plasma cells survive treatment with the immunolytic drugs studied, and that long-lived lymphocytes are specifically resistant to prednisone and cyclophosphamide. We believe these results have an application to the attempts to find drugs useful in the treatment of immunologic rejections of organ transplants, and for therapy of autoimmune diseases.
在二次免疫刺激后,对大鼠腘淋巴结细胞进行了4天的标记。在最后一剂氚标记胸腺嘧啶核苷给药31天后,开始对大鼠组每日进行腹腔注射泼尼松、环磷酰胺、6-巯基嘌呤或放线菌素D的疗程。这些药物最初的低剂量在连续几周内加倍,直到出现淋巴细胞发育不全或死亡。每周处死每组中的大鼠,并测定腘淋巴结中持续存在的、标记的小淋巴细胞的百分比。检查这些淋巴结切片中持续存在的、标记的浆细胞。在用泼尼松和环磷酰胺治疗期间,标记的淋巴细胞百分比增加,而淋巴细胞总数减少。泼尼松减少了长寿浆细胞的数量,但这些细胞对环磷酰胺具有优先抗性。在导致接受6-巯基嘌呤或放线菌素D的大鼠死亡之前,这两种药物对淋巴组织的组织学均无明显影响,对标记的长寿淋巴细胞和浆细胞的比例也无明显影响。这些结果表明,长寿淋巴细胞和浆细胞在接受所研究的免疫溶解药物治疗后仍能存活,并且长寿淋巴细胞对泼尼松和环磷酰胺具有特异性抗性。我们认为这些结果适用于寻找对治疗器官移植免疫排斥和自身免疫性疾病有用的药物的尝试。